The dose of cabergoline at first pregnancy was 0.25–9.00 mg per week in the cohort as a whole, and 2.00–9.00 mg per week in the women who were bromocriptine-resistant. No pregnancy-related ...

Although there are no head-to-head trials, available data cited above suggest that cabergoline may be more effective than bromocriptine in patients with Cushing's disease with a 30–40% response ...

Bromocriptine is a sympatholytic D2-dopamine agonist that has been approved for the treatment of type 2 diabetes. Based on animal and human studies, timed bromocriptine administration within 2 h ...